An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries

AIDS

Volumn 24, Issue 17, 2010, Pages 2603-2607

  Hoskins, Susan ^a   Weller, Ian ^b   Jahn, Andreas ^c,d   Kaleebu, Pontiano ^e   Malyuta, Ruslan ^f   Kirungi, Wilford ^g   Fakoya, Ade ^h   Porter, Kholoud ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c MINISTRY OF HEALTH   (Malawi)

^d International Training and Education Center on HIV   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f Perinatal Prevention of AIDS Initiative   (Ukraine)

^g MINISTRY OF HEALTH   (Uganda)

^h International HIV AIDS Alliance   (United Kingdom)

Author keywords

antiretroviral therapy; health status indicators; HIV; low income population; monitoring; outcome assessment; program evaluation

Indexed keywords

ARTICLE; CONSTRUCT VALIDITY; CONTENT VALIDITY; EXTERNAL VALIDITY; HEALTH CARE NEED; HEALTH PROGRAM; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INTERNAL VALIDITY; LOWEST INCOME GROUP; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SURVIVAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; HEALTH STATUS INDICATORS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 78349305438     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833dd0d3     Document Type: Article

References (21)

1. UNAIDS Online Indicator Registry http://www.indicatorregis-try.org/ public.aspx?view=home&public=1. [Accessed on 10 February 2010].
2. UNAIDS Indicator Registry, Indicator List: Antiretroviral Ther-apy (ART) http://www.indicatorregistry.org/public.aspx?view= browse&public= 1&catId=54. [Accessed on 9 March 2010].
3. UNAIDS, Monitoring the Declaration of Commitment on HIV/AIDS, Guidelines on construction of core indicators, 2010 reporting, UNAIDS 09, http://data.unaids.org/pub/Manual/2009/JC1676-Core-Indicators-2009-en.pdf. [Accessed on 13 October 2009]
4. WHO, Monitoringandreportingonthehealthsector'sresponse towards universal access to HIV/AIDS treatment, prevention, care and support 2009-2010. WHO framework for global monitoring and reporting, http://www.who.int/hiv/ universalac cess2010/hiv-me-framework-2009-10.pdf. [Accessed on 13 October 2009]
5. GFATM, Monitoring and Evaluation Tool Kit Part 2: Tools for monitoringprogramsfor HIV, Tuberculcosis, Malariaand health systems strengthening; HIV, 3rd ed. 2009. http://www.theglo balfund.org/documents/me/M- E-Toolkit-P2-HIV-en.pdf. [Accessed on 13 October 2009]
6. PEPFAR 2008, Next Generation of PEPFAR Indicators Project. http://www.pepfar.gov/documents/organization/99013.pdf. [Accessed on 9 September 2009]
7. Makombe S, Hochgesang M, Jahn A, Tweya T, Hedt B, Chuka S, et al. Assessing the quality of data aggregated by antiretroviral treatment clinics in Malawi. Bull World Health Organ 2008; 86:310-314.
8. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, Spohr M, et al. for the ART-LINC collaboration of the Inter-national Epidemiological Databases to Evaluate AIDS, Electro-nic medical record systems, data quality ad loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 2008; 86:939-947.
9. Malawi Ministry of Health, ART Report 2009, Q2. http://www. hivunitmohmw.org/uploads/Main/ART%20Report%202009% 20Q2. [Accessed 19 August 2009]
10. Brinkhof MWG, Pujades-Rodriguez P, Egger M, Mortality of patients lost to follow-up in antirretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. Plos One 4: e5790.
11. YU JK, Tok TS, Tsai JJ, Chang WS, Dzimadzi RK, Yen PH, et al., What happens to patients on antiretroviral therapy who trans-fer out to another facility? PLOS One 2008; 3:e2065.
12. Bärnighausen T. Reasons for loss to follow-up in antiretroviral treatment programs in South Africa. Future HIV Ther 2008; 2:141-145.
13. Losina E, Toure H, Uhler LM, Anglaret Z, Paltiel AD, Balestre E, et al. for the ART-LINC Collaboration of international epide-miological databases to evaluate AIDS (IeDEA) and the CEPAC International investigators. Cost-effectiveness of preventing loss to follow-up in HIV treatment programmes: a Cote d'Ivoire appraisal, PLoSMed2009; 6: e10000173.
14. WHO 2006, Patient monitoring guidelines for HIV care and ART. http://www.who.int/hiv/pub/ptmonguidelines.pdf. [Accessed 10 February 2010]
15. Bärnighausen T, Xolo V, Cooke G Evaluatingtheperformanceof antiretroviral treatment programs: mortality and loss to follow-up. PLoS Med 2007. http://www.plosmedicine.org/annotation/listThread.action?inReplyTo= info%3Adoi%2F10.1371%2Fan notation%2Fbbc7b42e-3ea0-47ba-ad73- 34fc9d6c410c&root= info%3Adoi%2F10.1371%2Fannotation%2Fbbc7b42e-3ea0-47 ba-ad73-34fc9d6c410c
16. Walker AS, Ford D, Mulenga V, Thomason MJ, Nunn A, Chintu C, et al. Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children. AIDS Behav 2009; 13:33-41; Epub 2008 Apr 10.
17. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE, Cowan FM et al. AIDS amongolder children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23:2039-2046.
18. Ferrand RA, Bandason A, Musvaire P, Larke N, Nathoo K, Mujuru H et al. Causesofacute hospitalization in adolescence: burden and spectrum ofHIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective study, PLoS Med 2010; 7: e1000178. doi: 10.1371/journal.pmed. 1000178.
19. Badri M, Wilson D, Wood R. Effect of highly active antiretro-viral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 239:2059-2064.
20. Brastein P, Brinkhof MWG, Dabis F, Schecter M, Boulle A, Miotti P, et al. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-in-come and high-income countries. Lancet 2006; 367:817-824.
21. Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, Chintu C, et al. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. JAcquir Immune Defic Syndr 2006; 42:637-645.